Department of Urology, Stony Brook University Hospital, Stony Brook, New York, USA.
Neurourol Urodyn. 2022 Aug;41(6):1373-1379. doi: 10.1002/nau.24955. Epub 2022 May 17.
Sacral neuromodulation (SNM) is third-line therapy approved for urge urinary incontinence (UUI) and urgency, and nonobstructive urinary retention. Multiple sclerosis (MS) patients often suffer from neurogenic lower urinary tract dysfunction (NLUTD). The utility of SNM in the MS population is limited by magnetic resonance imaging (MRI) incompatibility as routine MRIs to evaluate for disease progression are required. The Axonics System is the first Food and Drug Administration-approved SNM device that is 1.5/3 T full-body MRI-conditionally safe. This study seeks to investigate the symptomatic improvement in MS patients after implantation of the Axonics System.
All MS patients who elected for Axonics SNM from December 2019 to January 2021 were included. Demographics and scores were queried for urogenital distress inventory (UDI-6), incontinence impact questionnaire (IIQ-7), and global response assessment (GRA).
Fifteen MS patients with UUI were included. The time to follow-up averaged 121 days. On UDI-6, 12 patients reported improvement, 1 worsening, and 2 no change. Average UDI-6 scores before and after implantation were 56.6 and 25.2 (p < 0.0001). Improvements were significant for all questions under stress urinary incontinence, UUI, and voiding difficulty subcategories. On IIQ-7, 14 patients reported improvement and 1 reported worsening. Average IIQ-7 scores before and after implantation were 59.0 and 22.2 (p < 0.001). Improvements were significant for travel, social, and emotional subcategories, but not for physical activity. The average GRA score was 6 ("moderately improved").
The majority of MS patients reported significant initial improvement in UUI and associated quality of life measures on validated questionnaires after implantation of the Axonics System. Future studies are needed to determine the long-term outcomes and durability of this MRI full-body conditionally-safe system.
骶神经调节(SNM)是三线治疗方法,适用于急迫性尿失禁(UUI)和急迫性、非梗阻性尿潴留。多发性硬化症(MS)患者常患有神经源性下尿路功能障碍(NLUTD)。由于需要进行常规 MRI 以评估疾病进展,因此 MRI 不兼容限制了 SNM 在 MS 人群中的应用。Axonics 系统是首个获得美国食品和药物管理局批准的 1.5/3T 全身体 MRI 有条件安全的 SNM 设备。本研究旨在调查 Axonics 系统植入后 MS 患者的症状改善情况。
所有 2019 年 12 月至 2021 年 1 月选择 Axonics SNM 的 MS 患者均被纳入研究。对尿生殖窘迫量表(UDI-6)、失禁影响问卷(IIQ-7)和整体反应评估(GRA)的患者人口统计学数据和评分进行了查询。
纳入了 15 例 UUI 的 MS 患者。随访时间平均为 121 天。在 UDI-6 中,12 例患者报告改善,1 例恶化,2 例无变化。植入前后 UDI-6 评分分别为 56.6 和 25.2(p<0.0001)。在压力性尿失禁、UUI 和排尿困难亚类下,所有问题的改善均有统计学意义。在 IIQ-7 中,14 例患者报告改善,1 例报告恶化。植入前后 IIQ-7 评分分别为 59.0 和 22.2(p<0.001)。在旅行、社交和情绪亚类方面有显著改善,但在身体活动方面没有改善。平均 GRA 评分为 6(“中度改善”)。
Axonics 系统植入后,大多数 MS 患者在 UUI 和相关生活质量问卷上报告了显著的初始改善。需要进一步的研究来确定这种全身体 MRI 有条件安全系统的长期结果和耐久性。